Ultragenyx Pharmaceutical (RARE) Depreciation & Amortization (CF) (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has reported Depreciation & Amortization (CF) for 14 consecutive years, with $8.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Depreciation & Amortization (CF) fell 11.11% year-over-year to $8.0 million; the TTM figure through Mar 2026 stood at $34.0 million (down 5.96% YoY), while the FY2025 annual figure was $35.0 million, down 2.78% from the prior year.
• Depreciation & Amortization (CF) retreated to $8.0 million in Q1 2026 per RARE's latest filing, from $8.8 million in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $9.5 million in Q4 2024 and bottomed at $4.1 million in Q1 2022.
• Historically, Depreciation & Amortization (CF) has averaged $7.2 million across 5 years, with a median of $8.2 million in 2023.
• Annual changes were most pronounced in 2024 — Depreciation & Amortization (CF) jumped 68.93% — and 2026, when it decreased 11.11%.
• Ultragenyx Pharmaceutical's Depreciation & Amortization (CF) stood at $5.0 million in 2022, then surged by 65.66% to $8.2 million in 2023, then rose by 16.12% to $9.5 million in 2024, then declined by 7.88% to $8.8 million in 2025, then retreated by 8.94% to $8.0 million in 2026.
• Business Quant data shows RARE's Depreciation & Amortization (CF) at $8.0 million in Q1 2026, $8.8 million in Q4 2025, and $8.6 million in Q3 2025.